Skip to main content
. 2019 Jun 21;98(25):e16074. doi: 10.1097/MD.0000000000016074

Figure 2.

Figure 2

OS of patients with BCLC C stage HCC who underwent multiple-line therapies, as assessed by Kaplan–Meier analysis. Multiple-line treatments yielded a significantly better median OS than first-line treatment (P < .001) (A). Third-line treatments resulted in a significantly better median OS than first-line treatment (P = .015) (B). Treatments with or without sorafenib had a similar median OS (P < .001) (C). Multiple-line treatments with or without sorafenib yielded a significantly better median overall survival than sorafenib alone (P = .013) (D). BCLC = Barcelona clinic liver cancer, HCC = hepatocellular carcinoma, OS = overall survival.